VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.
about
Neuroprotection as a Therapeutic Target for Diabetic RetinopathyNRP1 function and targeting in neurovascular development and eye diseaseNovel therapies for open-angle glaucomaThe era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapyLosartan Treatment Protects Retinal Ganglion Cells and Alters Scleral Remodeling in Experimental GlaucomaImatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cellsThe nerve growth factor signaling and its potential as therapeutic target for glaucomaExperimental glaucoma induced by ocular injection of magnetic microspheres.Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.O-GlcNAc modification of transcription factor Sp1 mediates hyperglycemia-induced VEGF-A upregulation in retinal cells.Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathyDistal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism.Retinal pigment epithelial cells express a functional receptor for glucagon-like peptide-1 (GLP-1).Changes in Retinal Nerve Fiber Layer Thickness after Multiple Injections of Novel VEGF Decoy Receptor Conbercept for Various Retinal Diseases.Targeting Müller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity.Hypoxia-Inducible Factor-1α Target Genes Contribute to Retinal Neuroprotection.Effects of Ranibizumab and Aflibercept on Human Müller Cells and Photoreceptors under Stress Conditions.A Proinflammatory Function of Toll-Like Receptor 2 in the Retinal Pigment Epithelium as a Novel Target for Reducing Choroidal Neovascularization in Age-Related Macular Degeneration.Palmitic acid triggers cell apoptosis in RGC-5 retinal ganglion cells through the Akt/FoxO1 signaling pathway.Glaucoma: recent advances in the involvement of autoimmunity.Epigenetics and Signaling Pathways in Glaucoma.Effect of Anti-vascular Endothelial Growth Factor Antibody on the Survival of Cultured Retinal Ganglion Cells.A hypoxia-responsive glial cell-specific gene therapy vector for targeting retinal neovascularization.Differential apicobasal VEGF signaling at vascular blood-neural barriers.Modeling Glaucoma: Retinal Ganglion Cells Generated from Induced Pluripotent Stem Cells of Patients with SIX6 Risk Allele Show Developmental Abnormalities.[Neuroprotective approaches].Changes in Peripapillary Nerve Fiber Layer Thickness after Adjuvant Stereotactic Radiotherapy in Patients with Neovascular Age-Related Macular Degeneration.The Effect of Ranibizumab on Normal Neurosensory Retina in the Eyes of Patients with Exudative Age Related Macular Degeneration.Progression of Primary Open Angle Glaucoma in Diabetic and Non-diabetic Patients.Correlation between macular ganglion cell-inner plexiform layer thickness and visual acuity after resolution of the macular edema secondary to central retinal vein occlusion.BTBR ob/ob mouse model of type 2 diabetes exhibits early loss of retinal function and retinal inflammation followed by late vascular changesClinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
P2860
Q26749178-2D5D89BE-3297-4D94-9D51-A4DA052E51D8Q26765952-09810DB3-E510-49F0-A6EB-42FFFF13EB7DQ26851132-3292D045-46B8-4F05-B75C-21EB785208DFQ28067341-A8C152ED-F913-40ED-8551-2B4C37369087Q28550525-E0CB0C06-6CB5-4F2D-B842-19DC1E8908D7Q30579734-7215CA36-2C26-403D-9FEC-65669AE4FB20Q34182180-BAA41102-08AF-41D0-A4CC-6CD7DAB080AEQ35162164-5CBDDD29-4944-49F3-B5AF-07D9CD127AD3Q35696092-CF6357FB-8E24-495B-AD85-3094F88AEF41Q35970441-A5C5CB55-66EE-499B-B8E8-3D8859E9BA74Q36379513-71863528-FBFD-4BDB-B732-5D48295A4137Q37030276-00237E30-446F-4DE4-A57D-E59509CBF396Q37332471-2EC1C07D-5F30-4C5B-A9F2-E35056D0E7E2Q37476086-05C66638-801E-4D36-B979-8C313983F5ECQ37577214-0EF77F1F-A0EA-411D-89E7-753E28A18406Q37667292-9F90CAF7-5409-4034-8F03-E8D57EA89463Q37729097-F77662E0-3034-465E-B3C3-41E9C8860F26Q38663964-03E3D0BC-31B9-4BFE-8020-420F03315975Q38727187-C0143A31-7C53-4429-81E5-257BFA2A37D4Q38913448-0B8E4448-2DCA-4D74-B082-C6E42B8BD05EQ39140153-5C2B87E1-1FDF-4BE8-BFDA-1A26AE4564CDQ41221841-C97990C3-B7DA-4FB4-9FE8-DB965B9E5628Q41817953-A3CFCCD7-91DB-464D-8F0B-298E1F066832Q42030071-4A5DEA57-E343-45DE-B901-EC1FD1655329Q42777312-B338C9F6-A940-4DA4-84E7-6562F748AEB9Q44749277-897ACB0C-EEAF-453B-AF58-E476EC4E2759Q47942309-9F85E45D-C5A1-4998-9318-6BF7F0E7DEFCQ49334455-E0104643-598B-40E3-BD94-80AB545C8345Q49971181-086DEABC-8140-4595-84B0-B786EFFB9941Q50355167-51810E05-EC9C-4865-85EC-12812BC90B35Q58791858-00A31D59-DA11-4DE0-9591-422C724299A8Q59126137-DD6574D3-4C77-4AA1-B89B-7E37B9F8C3B1
P2860
VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
VEGF-A is necessary and suffic ...... dels of experimental glaucoma.
@ast
VEGF-A is necessary and suffic ...... dels of experimental glaucoma.
@en
type
label
VEGF-A is necessary and suffic ...... dels of experimental glaucoma.
@ast
VEGF-A is necessary and suffic ...... dels of experimental glaucoma.
@en
prefLabel
VEGF-A is necessary and suffic ...... dels of experimental glaucoma.
@ast
VEGF-A is necessary and suffic ...... dels of experimental glaucoma.
@en
P2093
P2860
P1476
VEGF-A is necessary and suffic ...... dels of experimental glaucoma.
@en
P2093
Arthur Finkelstein
David T Shima
James E Morgan
Peng T Khaw
Richard H Foxton
Sauparnika Vijay
Yin-Shan Ng
P2860
P304
P356
10.1016/J.AJPATH.2012.12.032
P407
P577
2013-02-12T00:00:00Z